SBIR-STTR Award

Large Scale Gene Targeting For Functional Genomics
Award last edited on: 3/4/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$99,743
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Theodore K Choi

Company Information

Axys Pharmaceuticals Inc (AKA: Sequana Therapeutics Inc~Akkadix Corporation)

180 Kimball Way
South San Francisco, CA 94080
   (858) 452-6550
   N/A
   www.axyspharm.com
Location: Single
Congr. District: 14
County: San Mateo

Phase I

Contract Number: 1R43GM56568-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1997
Phase I Amount
$99,743
We propose to develop technologies for making targeted gene inactivations in mice ten to fifty fold faster than is currently possible. Such "knockout" transgenic mice are critical for understanding gene function and disease processes at the organismal level. Instead of conventional approaches that rely on restriction enzymes to construct targeting vectors by recombinant DNA procedures, novel plasmids and methods for harnessing the recombinational machinery of bacteria to rapidly assemble targeting vectors will be developed. These vectors will be more precisely constructed and will be at least as efficient at homologous recombination than conventional targeting vectors. PROPOSED COMMERCIAL APPLICATION The development of efficient, large-scale gene targeting technologies will accelerate gene discovery and gene functional analysis providing for more rapid development of diagnostics and therapeutics for human genetic diseases. Valuable animal models for diseases will also be generated.

Thesaurus Terms:
biotechnology, gene targeting, genome, plasmid gene expression, method development, restriction endonuclease, transfection vector, transposon /insertion elementNational Institute of General Medical Sciences (NIGMS)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----